StreetInsider.com News Articles

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, click here.

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on

Thu, 26 Feb 2026 16:05:00 -0500

The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include:

Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell